Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Palomid 529 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Palomid 529 | DRUG | comparison of different dosages of drug |
Inclusion Criteria: * Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye. * Subfoveal choroidal neovascularization (CNV) due to AMD * Total area of the lesion (in...
Palomid 529 is an investigational small molecule being developed for the treatment of age-related macular degeneration (AMD), specifically advanced neovascular AMD. It is administered to patients aged 50 years and older. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Palomid 529 is a dual TORC1/2 inhibitor that targets the PI3K/Akt/mTOR signaling pathway. By inhibiting both TORC1 and TORC2 complexes, it aims to modulate cellular pathways involved in the progression of neovascular age-related macular degeneration.
Palomid 529 is being developed by CervoMed Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol CRVO. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with age-related macular degeneration.
Palomid 529 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 1 study has been completed, and the drug remains under investigation for the treatment of advanced neovascular age-related macular degeneration.
Palomid 529 has one completed clinical trial, identified as NCT01033721. This Phase 1 study evaluated the drug as a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway for advanced neovascular age-related macular degeneration. The trial enrolled 13 participants in the United States and was not randomized or double-blinded.